Dr. Gregory Daniel is an experienced leader in health policy, pharmaceutical policy, and real-world evidence (RWE) development and comparative effectiveness research (CER). He currently serves as the Deputy Center Director at the Duke-Margolis Center for Health Policy at Duke University and Clinical Professor in Duke's Fuqua School of Business where he directs the Washington, D.C. office of the Center and leads the Center's policy development efforts with a specific focus in pharmaceutical and medical device policy. Previously, he was Fellow and Managing Director in Economic Studies at the Brookings Institution and Vice President, Government and Academic Research at HealthCore, Inc. (subsidiary of Anthem, Inc).
Dr. Daniel has executive-level experience leading and growing new lines of business, setting strategic direction, and leading multi-organizational collaborations with the pharmaceutical industry, public and private payers, academia, and patient advocacy organizations. Dr. Daniel's policy expertise includes convening and policy development to support new value-based payment models for drugs and devices, new approaches for improving the use of real-world evidence (RWE) in drug development, payment, care delivery, and health reform, and improving regulatory science and drug development tools. His research expertise includes leading RWE studies, including health economics and outcomes research, comparative effectiveness research, and drug safety and pharmacoepidemiologic studies. He has strong research, data analytics and methodology skills and significant experience utilizing real-world data (RWD) such as electronic administrative claims, laboratory results, registries, and electronic medical records to generate evidence that informs healthcare decisions, supports regulatory science, and payment.